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Abstract
Background: Adding bevacizumab to chemotherapy improves response rates and progression-free survival (PFS) in
metastatic breast cancer (mBC). We aimed to demonstrate decreased toxicity with metronomic chemotherapy/
bevacizumab compared with paclitaxel/bevacizumab.
Methods: This multicenter, randomized phase III trial compared bevacizumab with either paclitaxel (arm A) or daily
oral capecitabine-cyclophosphamide (arm B) as first-line treatment in patients with HER2-negative advanced breast
cancer. The primary endpoint was the incidence of selected grade 3–5 adverse events (AE) including: febrile
neutropenia, infection, sensory/motor neuropathy, and mucositis. Secondary endpoints included objective response
rate, disease control rate, PFS, overall survival (OS), quality of life (QoL), and pharmacoeconomics. The study was
registered prospectively with ClinicalTrials.gov, number NCT01131195 on May 25, 2010.
Results: Between September 2010 and December 2012, 147 patients were included at 22 centers. The incidence of
primary endpoint-defining AEs was similar in arm A (25 % [18/71]; 95 % CI 15–35 %) and arm B (24 % [16/68]; 95 %
CI 13–34 %; P = 0.96). Objective response rates were 58 % (42/73; 95 % CI 0.46–0.69) and 50 % (37/74; 95 % CI 0.39–
0.61) in arms A and B, respectively (P = 0.45). Median PFS was 10.3 months (95 % CI 8.7–11.3) in arm A and 8.
5 months (95 % CI 6.5–11.9) in arm B (P = 0.90). Other secondary efficacy endpoints were not significantly different
between study arms. The only statistically significant differences in QoL were less hair loss and less numbness in
arm B. Treatment costs between the two arms were equivalent.
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Conclusion: This trial failed to meet its primary endpoint of a reduced rate of prespecified grade 3–5 AEs with
metronomic bevacizumab, cyclophosphamide and capecitabine.
Keywords: Metronomic chemotherapy, Bevacizumab, Breast cancer, Toxicity
Background
While there is no generally accepted, optimal first-line
chemotherapy regimen for mBC, most experts favor the use
of taxanes and anthracyclines, either as monotherapy or in
different two-drug combinations. Combination regimens
typically achieve superior response rates (RR) and longer
PFS than mono-chemotherapy, but have limited impact on
OS [1–4] and are associated with increased toxicity [5].
The E2100 randomized phase III trial reported a near
doubling of PFS and RR with paclitaxel plus bevacizumab
compared with paclitaxel alone in patients with mBC [6].
Increased rates of sensory neuropathy, febrile neutropenia
and infection, and severe fatigue occurred with combin-
ation therapy. These data led to the FDA (Food and drug
administration) granting accelerated approval to bevacizu-
mab plus weekly paclitaxel for the first-line treatment of
HER2-negative mBC in 2008. However, this approval was
later removed because: additional randomized trials [7, 8]
showed less pronounced PFS and RR benefits; no trial dem-
onstrated an OS benefit (later confirmed in meta-analyses
[9, 10]); and additional safety concerns were discussed [11].
Metronomic chemotherapy is the frequent administration
of chemotherapy at low, minimally-toxic doses with no
prolonged drug-free intervals [12]. No trial has directly
compared bevacizumab plus paclitaxel with bevacizumab
plus metronomic cyclophosphamide-capecitabine. How-
ever, between-trial comparisons suggest that these regimens
have similar efficacy but that toxicity with metronomic
therapy is substantially reduced [6, 13]. We therefore
designed a randomized phase III trial to test if metronomic
chemotherapy plus bevacizumab decreases high-grade
toxicity compared with paclitaxel plus bevacizumab.
Methods
Patients
Eligible patients had cytologically/histologically proven
metastatic or locally recurrent inoperable HER2-negative
breast cancer evaluable according to RECIST v1.1 criteria
[14]. Other inclusion criteria included WHO (World
Health Organization) performance status 0–2, low-risk for
bleeding, and available baseline QoL and pharma-
coeconomic assessment. Patients with (neo)adjuvant
chemotherapy within the previous 6 months (12 months
for taxane- and 5-FU-based chemotherapy), anti-VEGF
(vascular endothelial growth factor) therapy within the
previous 12 months, or prior chemotherapy for metastatic
or locally advanced/recurrent breast cancer were excluded.
Other exclusion criteria comprised known CNS
(Central Nervous System) metastases; severe cardiovas-
cular, renal, hepatic, or neurological disease; and history
of abdominal fistula, gastrointestinal perforation, or
intra-abdominal abscess.
Trial design
This multicenter, randomized parallel open-label phase III
trial compared bevacizumab plus paclitaxel versus bevaci-
zumab plus metronomic capecitabine-cyclophosphamide
as first-line therapy in patients with HER2-negative meta-
static or locally recurrent breast cancer.
Patients received 10 mg/kg i.v. bevacizumab every
2 weeks with either 90 mg/m2 i.v. paclitaxel (days 1/8/15
of a 4 week cycle; arm A [6]) or daily oral 50 mg
cyclophosphamide and 3x500 mg capecitabine (arm B
[13]). All medications were given until disease progression
(PD), unacceptable AE according to local investigator’s
assessment, or consent withdrawal. After occurrence of an
unacceptable AE to one drugs, the remaining tolerated
drug(s) was (were) given until PD, consent withdrawal, or
unacceptable AE.
Treatments were assigned online (www.sakk.ch/sinatras).
Randomization (1:1) using minimization was stratified
according to measurable/evaluable disease, WHO perform-
ance status (0/1 vs. 2), and center.
Endpoints
The primary endpoint was the incidence of pre-specified
grade 3–5 AEs (CTCAE =Common Terminology Criteria
for Adverse Events, version 4.0) occurring during the trial
or within 30 days of last treatment, regardless of the causal
relationship to the trial drugs. These comprised: any AEs
of the system/organ classes infection and infestation,
febrile neutropenia, nausea, vomiting, oral mucositis,
peripheral sensory neuropathy, arthralgia, myalgia, head-
ache, thromboembolic events, cerebrovascular ischemia,
left ventricular systolic dysfunction; any AEs correlated
with bleeding; or any gastrointestinal perforation.
Palmar-plantar erythrodysesthesia syndrome (hand-foot
syndrome, HFS), a key toxicity of capecitabine, was not a
primary endpoint-defining AE in our protocol as grade 3/
4 HFS was not previously observed with metronomic
cyclophosphamide-capecitabine plus bevacizumab [13].
To exclude a potential bias caused by this omission we
performed an exploratory sensitivity analysis that included
HFS grade ≥3 as an event.
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Secondary endpoints included: objective response rate,
disease control rate, PFS, OS, other AEs, QoL, and
pharmacoeconomics.
The primary QoL endpoint was physical well-being
measured by self-assessment questionnaire at baseline
(pre-randomization) and at monthly clinic visits for the
first 12 months until PD. The questionnaire comprised
indicators of physical well-being, mood, coping effort,
overall treatment burden, health perception, appetite,
tiredness, hair loss, nausea/vomiting, and numbness/tin-
gling in hands/feet [15–20]. Higher scores (range 0–100)
reflected a better condition. A change from baseline in
physical well-being of ≥6 points was defined as clinically
meaningful [21]. An improvement of this magnitude
maintained for ≥12 consecutive weeks was defined as
QoL benefit.
Health economic analysis (HEA)
The primary endpoint of the HEA was the total incurred
treatment costs until patients stopped trial treatment.
The HEA adopted a health system perspective including
all substantial direct medical costs incurred in the treat-
ment of the patient. Health-related QoL was measured
using EQ-5D (EuroQOL five dimensions questionnaire).
Statistical methods
Sample size was estimated for the primary endpoint using
East 5.0 and adjusted with the Casagrande-Pike-Smith
correction. The expected incidence rate of predefined
grade 3–5 AEs was 30 % in arm A and 10 % in arm B.
With a two-sided 5 % type I error probability and 80 %
power, 71 evaluable patients per arm were required. The
primary endpoint was analyzed in all evaluable patients
(patients who received the first bevacizumab administra-
tion of the second cycle or who experienced a primary
endpoint-defining event), secondary exploratory efficacy
endpoints were analyzed among all randomized patients,
and secondary exploratory safety endpoints were analyzed
among all randomized patients who received ≥1 dose of
trial medication. All analyses were conducted using SAS
9.2 and R 3.0.0.
95 % confidence intervals were calculated for rates and
arms were compared using two-sided z-tests with pooled
variance and continuity correction. Time-to-event data
were analyzed by Kaplan-Meier analyses and compared
using log-rank tests or Gray-Tsiatis tests for cure models.
The effects of treatment allocation and time on
QoL scores were estimated using mixed linear models
for repeated measurements (without controlling for
multiple testing).
Differences in treatment costs between arms in the
HEA were tested by the Wilcoxon rank-sum test. A global
multivariable linear model (proc genmod) with a gamma
distribution and a logarithmic link function was used to
analyze costs after controlling for age.
Results
From September 2010 through December 2012, we
randomized 147 patients to bevacizumab plus paclitaxel
(N = 73; arm A) or metronomic therapy (N = 74; arm B) at
22 SAKK centers in Switzerland (Fig. 1). Patient character-
istics are listed in Table 1.
Safety
The primary endpoint was evaluable in 139 patients. A
primary endpoint-defining AE occurred in 18/71(25 %;
95 % CI 15–35 %) patients in arm A and 16/68 (24 %;
95 % CI 13–34 %) in arm B (P = 0.96). These AEs
comprised neuropathy (N = 7), infection (N = 5), thrombo-
embolic events (N = 3), arthralgia (N = 2), and nausea (N
= 1) in arm A, and infection (N = 4), thromboembolic
events (N = 4), nausea (N = 3), arthralgia (N = 2), headache
(N = 2), and mucositis (N = 1) in arm B. Only one of these
AEs was grade 4 (a thromboembolic event in arm A).
Results were similar in the sensitivity analysis that
included HFS as a primary endpoint-defining AE: 18
(25 %) patients in arm A and 19 (28 %) in arm B had an
event (P = 0.88).
Seventeen patients stopped treatment because of
unacceptable toxicities: 12 (17 %) in arm A and five
(7 %) in arm B. The main toxicities leading to suspen-
sion or delay were neuropathy, neutropenia, leukopenia,
fatigue, and infection for paclitaxel; HFS, neutropenia,
nausea/vomiting, and loss of appetite for capecitabine;
and vomiting/nausea, thrombocytopenia, diarrhea, and
neutropenia for cyclophosphamide.
Efficacy
Objective RRs were 58 % (42/73; 95 % CI 46–69 %) and
50 % (37/74; 95 % CI 39–61 %) in arms A and B, respect-
ively (P = 0.45). Four and two patients in arms A and B, re-
spectively, achieved a complete response. Disease control
rates were similar between arms (79 % [95 % CI 70–89 %]
in arm A and 64 % [95 % CI 53–74 %] in arm B).
At data cutoff, 103 patients had progressed. Median
PFS did not differ between study arms (P = 0.83; Table 2
and Fig. 2).
Seventy-two patients died during a median 26.1 months
follow-up (Table 2). OS was numerically higher in arm A
vs arm B (P = 0.24).
QoL
QoL forms were available for 82 % of patients. Patients
in arm B reported substantially less hair loss (p < 0.0001;
Fig. 3) and less numbness with increasing time (p < 0.01)
than those in arm A, and a tendency toward less overall
treatment burden (P = 0.11). Over the first 12 months
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treatment, 14/70 (20 %) patients in arm A and 14/73
(19 %) in arm B indicated a QoL benefit of a similar me-
dian duration (140 and 139 days, respectively).
HEA
By January 2014, 129 patients had stopped trial treatment
(Table 3). There was no cost advantage for bevacizumab
plus metronomic chemotherapy over bevacizumab plus
paclitaxel. Mean total incurred treatment costs were CHF
(Swiss Francs) 69,474 (~US$75,000) for arm A and CHF
80,324 (US$86,600) for arm B. Age did not significant
effect the results.
Discussion
We evaluated a combination of metronomic chemother-
apy and bevacizumab that was described as effective and
almost non-toxic in a small phase II trial [13]. We focused
on grade 3/4 toxicities that are associated with a decrease
in QoL and considerable additional treatment costs.
We could not demonstrate a superior toxicity profile
of bevacizumab plus metronomic chemotherapy com-
pared with bevacizumab plus paclitaxel. However, there
seem to have been some qualitative differences in terms
of toxicity. For instance, no grade 3/4 neuropathy was
observed in the metronomic arm, whereas this adverse
event occurred in almost 10 % of patients treated with
paclitaxel. This toxicity is well-known to be associated
with all taxanes, and especially with paclitaxel when
given in a weekly regimen. Furthermore, we observed
less treatment interruptions due to unacceptable toxicity
in the metronomic (7 %) versus the paclitaxel arm
(17 %). Although these differences were not statistically
significant due to lack of power, it is highly likely that a
larger study would have shown a significantly lower rate
of at least some of these toxicities in the metronomic
arm of the study.
The high rate of primary endpoint-defining grade 3/4
AEs in the metronomic arm of our trial is difficult to
explain. These occurred in 24 % of patients in our trial
but were absent in the previous phase II trial [13]. This
finding might reflect differences between study popula-
tions or differences in reporting of AEs, due to the
specific focus on these events in our trial. One quarter
of paclitaxel-treated patients in our trial experienced
Fig. 1 CONSORT diagram. The flow diagram shows the intention-to-treat population of 147 patients included in the primary analysis of
bevacizumab plus paclitaxel (arm A) compared with bevacizumab plus metronomic chemotherapy (arm B). Bev=bevacizumab;
PD=progressive disease
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primary endpoint-defining AEs, close to the incidence
seen in E2100 (36 %) [6], and in more recent studies of
bevacizumab in breast cancer [22]. We therefore assume
that our patient population was not substantially differ-
ent from that of other studies [13].
The PFS of 10.3 months observed in the taxane arm of
our trial is in line with other randomized trials of first-line
taxane/bevacizumab combinations (range 9.2–11.3 months)
[6–8]. The PFS in the metronomic arm of our trial
(8.5 months) is comparable to that reported in the phase II
trial (10.5 months), though this trial also included patients
in subsequent lines of therapy for advanced breast cancer
[13]. Similarly, the RRs in our trial (paclitaxel arm: 58 %;
metronomic arm: 50 %) are consistent with RRs in the trials
upon which our study was based (E2100/RIBBON1: 37–
51 %; Dellapasqua et al: 48 % [6, 8, 13]). Interestingly, a
small phase II trial in 26 patients using the same metro-
nomic therapy protocol (capecitabine, cyclophosphamide,
and bevacizumab) in the same patient population (HER-2
negative mBC) as in our trial, but adding erlotinib 100 mg
daily, reported a response rate of 62 % and a time to pro-
gression of 10 months compatible with but by no means
proving a possible additional benefit of EGFR-inhibition in
this population [23].
The QoL benefit based on patient-reported outcomes
was comparable between arms. However, the reduced in-
cidence of alopecia and numbness seen with metronomic
chemotherapy might still make this regimen attractive to
a substantial number of patients. The HEA failed to dem-
onstrate a cost benefit of bevacizumab plus metronomic
chemotherapy over bevacizumab plus paclitaxel. While
treatment costs were not significantly different between
study arms, mean (but not median) total costs were
surprisingly higher when bevacizumab was combined with
oral metronomic therapy versus paclitaxel. This finding
is somewhat surprising on the background of previ-
ous studies and a recent review suggesting metro-
nomic chemotherapy as a low-cost, well-tolerated,
and easy to access strategy even in resource-limited
countries [24].
It is tempting to speculate that both, the lack of bene-
fit in QoL and the relatively high treatment costs in the
metronomic compared to the standard arm are due to
the unexpectedly high level of toxicity seen with metro-
nomic chemotherapy in our trial.
Another possible explanation of the somewhat sur-
prising results of our study could be subtle differences in
the study populations, with for instance lung metastases
being over-represented in the metronomic arm, while
soft-tissue and other types of metastases appear to be
more frequent in the paclitaxel arm. The randomization
of patients was stratified according to measurable versus
evaluable disease, performance status 0/1 versus 2, and
center, which lead to a balanced distribution of these
potentially prognostic/predictive factors between the two
study arms. However, because of the relatively small
number of cases in the trial it is impossible to determine
the influence of additional factors such as the localization
of metastases on our results.
Table 2 Progression free (PFS) and overall survival (OS)
Arm A (N = 73) Arm B (N = 74)
PFS
Events, n (%) 49 (67.1 %) 54 (73.0 %)
Censored, n (%) 24 (32.9 %) 20 (27.0 %)
Median (95 % CI), months 10.3 (8.7, 11.4) 8.5 (6.5, 11.9)
Log-rank test P-value 0.83
OS
Events, n(%) 33 (45.2 %) 39 (52.7 %)
Censored, n (%) 40 (54.8 %) 35 (47.3 %)
Median (95 % CI), months 25.6 (18.9, NA) 18.7 (14.6, NA)
Log-rank test P-value 0.24
CI confidence interval
Table 1 Characteristics of patients in the primary analysis
according to chemotherapy cohort
Characteristic Arm A
(N = 71)
Arm B
(N = 68)
Age – median (range) 64 (30–82) 62 (29–81)
WHO performance status, n (%)
0, 1 66 (93.0 %) 64 (94.1 %)
2 5 (7.0 %) 4 (5.9 %)
Previous (neo-)adjuvant chemotherapy, n (%) 38 (53.5 %) 37 (54.4 %)
Previous taxane-based chemotherapy, n (%) 21 (29.6 %) 20 (29.4 %)
Estrogen-receptor status, n (%)
negative 10 (14.1 %) 15 (22.1 %)
positive 61 (85.9 %) 52 (76.5 %)
unknown 1 (1.5 %)
Progesterone-receptor status, n (%)
negative 23 (32.4 %) 27 (39.7 %)
positive 48 (67.6 %) 40 (58.8 %)
unknown 1 (1.5 %)
Disease evaluation, n (%)
Evaluable 13 (18.3 %) 8 (11.8 %)
Measurable 58 (81.7 %) 60 (88.2 %)
Presence of metastases, n (%)
Liver 41 (57.7 %) 37 (54.4 %)
Lung 25 (35.2 %) 33 (48.5 %)
Bone 52 (73.2 %) 49 (72.1 %)
Brain 0 (0 %) 0 (0 %)
Soft-tissue 12 (16.9 %) 8 (11.8 %)
Other 21 (29.6 %) 13 (19.1 %)
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Fig. 2 Progression free survival according to treatment arm. The continuous line indicates the standard arm (a), the dashed line the experimental arm (b)
Fig. 3 Physical well-being, hair loss, numbness, treatment burden, mood and coping effort. Data are means with 95 % CIs from baseline over 12
treatment cycles with the number of patients for each cycle. Higher scores indicate better condition. The continuous lines indicate the standard
arm (a), the dashed lines the experimental arm (b)
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Conclusions
In conclusion, we were unable to achieve a better safety
and efficacy profile for bevacizumab by combining with
metronomic chemotherapy compared with paclitaxel. We
therefore do not recommend further testing of this regimen
of bevacizumab plus metronomic chemotherapy in mBC.
Key message
Combining bevacizumab with metronomic cyclophospha
mide-capecitabine does not achieve a superior safety and
efficacy profile compared with bevacizumab plus paclitaxel
in patients with advanced HER2 (human epidermal growth
factor receptor 2)-negative breast cancer.
Additional file
Additional file 1: Table S1. Unit costs for the health economics
analysis. (DOCX 16 kb)
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